Assertio Therapeutics, Inc. (ASRT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ASRT POWR Grades
- Sentiment is the dimension where ASRT ranks best; there it ranks ahead of 96.19% of US stocks.
- ASRT's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- ASRT ranks lowest in Growth; there it ranks in the 0th percentile.
ASRT Stock Summary
- Revenue growth over the past 12 months for Assertio Holdings Inc comes in at -41.71%, a number that bests just 8.57% of the US stocks we're tracking.
- The volatility of Assertio Holdings Inc's share price is greater than that of 95.32% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ASRT comes in at 79.24% -- higher than that of 97.5% of stocks in our set.
- Stocks that are quantitatively similar to ASRT, based on their financial statements, market capitalization, and price volatility, are QUMU, IMXI, LXFR, WD, and CSGS.
- ASRT's SEC filings can be seen here. And to visit Assertio Holdings Inc's official web site, go to www.assertiotx.com.
ASRT Price Target
For more insight on analysts targets of ASRT, see our ASRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.20 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ASRT Stock Price Chart Interactive Chart >
ASRT Price/Volume Stats
| Current price | $1.63 | 52-week high | $5.80 |
| Prev. close | $1.71 | 52-week low | $1.32 |
| Day low | $1.63 | Volume | 694,100 |
| Day high | $1.72 | Avg. volume | 3,113,706 |
| 50-day MA | $1.92 | Dividend yield | N/A |
| 200-day MA | $2.50 | Market Cap | 70.82M |
Assertio Therapeutics, Inc. (ASRT) Company Bio
Assertio Therapeutics, Inc. (formerly DepoMed) develops products for pain and other central nervous system conditions in the United States. The company was founded in 1995 and is focused in Newark, California.
Latest ASRT News From Around the Web
Below are the latest news stories about Assertio Holdings Inc that investors may wish to consider to help them evaluate ASRT as an investment opportunity.
Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price RequirementLAKE FOREST, Ill., June 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). Accordingly, the Company has regained comp |
5 Reddit Cryptos Seeing the Most Chatter FridayIt's another busy day of trading and where would we be without Reddit rising interest in various penny stocks with its chatter? |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're really starting to get into earnings season with many of the biggest pre-market stock movers today connected to earnings news. |
Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)Collaboration will Increase Access to CAMBIA and SPRIX through Cove’s Innovative, and Continuous Online Physician CareLAKE FOREST, Ill. and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT), and Cove, a leading migraine telemedicine platform, today announced a collaboration to make CAMBIA (diclofenac potassium) for oral solution and SPRIX (ketorolac tromethamine) nasal spray available to Cove’s patient population. This collaboration will make it easier for more patients to gain access to high-quality physician care. Using Cove’s online telemedicine platform, patients complete a consultation with a licensed physician who can prescribe a variety of treatment options, including CAMBIA for a patient’s acute treatment of migraine ... |
Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021LAKE FOREST, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2021 financial results on Thursday, May 6, 2021, after the close of markets. Following the release of its financial results, Assertio’s management will host a conference call beginning at 4:30 p.m. eastern time. Date:Thursday, May 6, 2021Time:4:30 p.m. Eastern TimeDial-in numbers:1-888-771-4371 (domestic) 1-847-585-4405 (international)Conference number:50155264 The live webcast and replay may be accessed at https://investor.assertiotx.com/. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. ... |
ASRT Price Returns
| 1-mo | 9.40% |
| 3-mo | -56.19% |
| 6-mo | 14.56% |
| 1-year | -51.77% |
| 3-year | -94.46% |
| 5-year | -97.91% |
| YTD | 13.95% |
| 2020 | -71.39% |
| 2019 | -65.37% |
| 2018 | -55.16% |
| 2017 | -55.33% |
| 2016 | -0.61% |
Continue Researching ASRT
Here are a few links from around the web to help you further your research on Assertio Therapeutics Inc's stock as an investment opportunity:Assertio Therapeutics Inc (ASRT) Stock Price | Nasdaq
Assertio Therapeutics Inc (ASRT) Stock Quote, History and News - Yahoo Finance
Assertio Therapeutics Inc (ASRT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...